Seach Medical: Pharmacy Economics After the Impairment
The NIS 8.0 million pharmacy impairment is not accounting noise. With retail revenue still almost flat, goodwill written down again, and management still talking about a move to profitability, the real question is no longer whether the network adds volume, but whether it actually earns an adequate return.
Where the Real Economic Signal Sits
The main article argued that Seach ended 2025 with stronger cash and balance-sheet resilience than the headline accounting numbers suggest, but still without full proof that its vertically integrated platform is already producing a higher earnings tier. This follow-up isolates the retail layer, because this is exactly where that promise was supposed to turn from a strategic story into visible economics.
The first point is that the pharmacy revenue line did not break, but it also did not lift off. Retail revenue was NIS 60.4 million in 2025, versus NIS 61.7 million in 2024 and NIS 62.8 million in 2023. In other words, the network is providing some stability, but not the kind of growth that can justify the acquisition premium and the vertical-synergy story on its own.
The second point is that the NIS 8.036 million impairment in 2025 did not come out of nowhere. This is now the third consecutive year in which this layer has seen goodwill write-downs. The total goodwill balance fell from NIS 30.4 million at the start of 2023 to NIS 14.3 million at the end of 2025, after cumulative write-downs of NIS 16.1 million. That is no longer a one-off event. It is a repricing of expectations.
The third point is that management itself still describes the pharmacy layer as a project of growing activity and moving to profitability. That is an important admission. If the next 12 months are still framed as a transition to profitability, then the network is not there yet. At the same time, after the balance-sheet date the group signed a merger agreement with Shafa Kaan. That likely reflects another step in simplification and deeper integration, but it does not by itself answer the central question: is the network generating an adequate return on the capital and goodwill built around it?
The Retail Revenue Line Barely Moved
Seach owns 6 pharmacies and presents them as one of the key advantages of its Israeli strategy: a broader customer base, stronger contact with the end customer, and a more diversified revenue mix. At the revenue level, that argument is partly true. The network did help stabilize the group in a year when wholesale activity moved backward.
But that stability is not the same as good economics. Retail revenue fell 2.1% in 2025, after a 1.7% decline in 2024. Over the last three years, the retail line has been almost flat. Retail’s share of group revenue rose to 38.4% in 2025, but that happened mainly because wholesale revenue fell 12.0% to NIS 96.8 million, not because the pharmacy layer opened a new growth engine.
That distinction matters. If the pharmacy network were already generating real value creation, one would expect at least one of three things to be visible: clear revenue growth, disclosed profitability improvement in the layer itself, or no renewed need to cut goodwill. What the numbers show today is a different mix: a relatively stable revenue line, no visible proof of pharmacy profitability, and another sharp write-down.
Put differently, the network is still playing more of a defensive role than a value-creation role. It brings Seach closer to the end customer, allows the group to sell through a controlled channel, and reduces theoretical dependence on someone else’s shelf. But the numbers still do not show a new return layer.
Another point readers can miss is that the report discloses the revenue split between retail and wholesale, but not a separate profit line for the pharmacies. That is why the impairment test ends up becoming one of the clearest direct economic signals available on the quality of the retail layer. When there is no full pharmacy profitability disclosure, the valuation test matters even more.
The Impairment Did Not Start in the Fourth Quarter
The NIS 8.036 million charge matters not just because of its size, but because of what it says about the direction of assumptions. The 2025 impairment review was based on value in use, using 5 years of projected cash flows plus a representative year, with 1.8% long-term sales growth, a 21% to 30% gross-margin range, and a 14.4% pre-tax discount rate. Even with that framework, the group revised cash-flow expectations downward and concluded that some of the cash-generating units in the pharmacy layer were worth less than their carrying value.
The split itself says a lot. Most of the hit came from Tifrachat, with an impairment of NIS 6.092 million against a recoverable amount of NIS 5.506 million. Even Hen absorbed NIS 1.576 million against NIS 2.892 million, and Pharma 10 another NIS 368 thousand against NIS 2.038 million. Once more conservative cash-flow assumptions are applied, part of the value previously carried simply does not hold.
The real importance sits in the sequence. In 2024 the group had already identified an impairment trigger at Shafa Kaan after a downward revision in projected cash flows, and booked a NIS 2.274 million write-down. Before that, in 2023, the same unit had already taken a NIS 5.757 million impairment. So 2025 is not the year the problem appeared. It is the year the problem spread to additional units.
And even after the write-down, the cushion does not look especially wide. In the sensitivity analysis, a 0.5% increase in the pre-tax discount rate would have added another NIS 452 thousand of impairment across the three units, while a 0.5% reduction in long-term sales growth would have added another NIS 330 thousand. That is not large relative to the impairment already booked, but it does show that the model remains sensitive to relatively small assumption changes.
| Unit | 2025 impairment | Recoverable amount | Extra impairment if discount rate rises by 0.5% | Extra impairment if long-term sales growth falls by 0.5% |
|---|---|---|---|---|
| Tifrachat | NIS 6.092 million | NIS 5.506 million | NIS 252 thousand | NIS 155 thousand |
| Even Hen | NIS 1.576 million | NIS 2.892 million | NIS 117 thousand | NIS 84 thousand |
| Pharma 10 | NIS 368 thousand | NIS 2.038 million | NIS 83 thousand | NIS 91 thousand |
What really matters is the type of disappointment these numbers reveal. This is not a sudden collapse in retail sales. It is a reset in expected future cash generation. And when a layer acquired to strengthen the end-customer relationship and deepen vertical synergy keeps losing valuation support for three straight years, the problem sits in the economics of the layer, not only in quarter timing.
What Management Is Still Trying to Get Out of the Network
Seach’s retail strategy is framed quite consistently. The company stresses that it sells across all licensed pharmacies in Israel, including the 6 pharmacies it controls. The logic is straightforward: more control over the channel, more contact with the end customer, more revenue diversification, and less reliance on someone else deciding what gets promoted on the shelf.
At the broader strategy level, the group also describes the network as part of a wider vertical-synergy effort, with explicit emphasis on increasing sales in the pharmacies it controls, especially sales of Seach-branded products. That is not a side detail. It is exactly the promise being tested here: not just owning a network, but using it to improve the economics of the full chain.
But alongside that promise, management’s 12-month outlook sounds much less celebratory. In distribution and sales, the company says it is working to stabilize the existing activity, expand volume, and move to profitability. That is the heart of the story. If profitability is still a forward goal, the network has not completed the proof phase. The physical structure exists, but the economics are still catching up.
That means the impairment does not contradict the strategy. It tests the strategy. The network may still be important to the group commercially, operationally, and from a branding standpoint. But until that importance also shows up in profitability and cash generation inside the layer itself, it remains a strategic move that still needs economic proof.
The Shafa Kaan Merger Signals Simplification, Not Proof of Value
After the balance-sheet date, the group signed a merger agreement with Shafa Kaan that is meant to be completed at the end of March 2026, subject to conditions and approvals. The timing is hard to ignore. After a sequence of goodwill write-downs in the retail layer, Seach is still reworking the legal and organizational structure of that layer as well.
There are two ways to read that move. The positive reading is that the group is trying to remove complexity, shorten internal layers, and centralize activity after several years of acquisitions and integration. That makes sense. A retail layer spread across separate entities can make management, control, and synergy extraction harder than it needs to be.
But there is also a more cautious reading, and for now it is the more convincing one. Structural simplification is not a substitute for economics. Even if the merger reduces friction, it does not retroactively change the fact that the retail line barely grew, goodwill was written down again, and management still defines profitability as a target rather than an achieved outcome. So the merger is interesting, but it is not the event that ends the debate.
What Has to Happen Now for the Story to Change
For the market to start reading the pharmacy layer differently, three things need to happen together. The first is growth, or at least a clear stop to the stagnation, in retail revenue itself. The second is a clearer signal that the layer is moving into profitability, not just in language but in results. The third is that the Shafa Kaan merger and the continued integration of the network actually simplify the structure and allow management to push more Seach products through the channel it controls.
| Checkpoint | What needs to show up | What would weaken the thesis |
|---|---|---|
| Retail revenue | A clear end to the stagnation around NIS 60 million and a return to growth | Another almost flat year would suggest a network that preserves volume but does not create a new engine |
| Network profitability | A move from a forward target to visible operating proof that the remaining goodwill is justified | Continued need for write-downs or even more cautious management language |
| Structural integration | Shafa Kaan’s merger and a cleaner structure without signs of fresh execution friction | A structural change with no economic change would leave the network as an organizational move only |
Bottom Line
The 2025 impairment matters less as an accounting headline and more as an economic diagnosis. It says that Seach’s pharmacy layer still has activity, customers, and presence, but has not yet proved that it is worth the value built around it during the acquisition years. In value-chain terms, the pharmacies still look more like a stabilization and distribution layer than a strong profit layer.
That does not mean the strategy has failed. It does mean the vertical integration story is still incomplete. If 2026 brings retail growth, a clearer sign of profitability, and structural simplification that actually translates into execution, the network’s economics can look very different. If not, the 2025 impairment will be remembered as the moment when both the market and the filing stopped talking about promise and started measuring return.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.